CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 509 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing MOST POPULAR ΟΓΚΟΙ ΕΓΚΕΦΑΛΟΥ February 10, 2019 Doxorubicin and Trabectedin Combination Improves Survival Among Patients with Metastatic or... September 13, 2024 Mom Of Two Diagnosed With Breast Cancer At 31: “I Just... February 28, 2020 Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer December 15, 2023 Load more HOT NEWS Biomarker Data from the KAITLIN Study in High-Risk Early Breast Cancer ASCO Annual Meeting 2023: Improving Patients’ Lives Through Collaboration, Research, and... FDA Approval of KRAS Inhibitor Sotorasib for Lung Cancer Hailed as... Five Questions with…Jennifer.
